Mersana Therapeutics Stock Forecast, Price & News

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has increased by 285.3% and is now trading at $24.89.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mersana Therapeutics.

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Mersana Therapeutics.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its earnings results on Monday, November, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.02. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.43 million. Mersana Therapeutics had a negative net margin of 4,119.91% and a negative return on equity of 54.92%.
View Mersana Therapeutics' earnings history.

6 equities research analysts have issued twelve-month price objectives for Mersana Therapeutics' stock. Their forecasts range from $20.00 to $32.00. On average, they expect Mersana Therapeutics' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Mersana Therapeutics.

Some companies that are related to Mersana Therapeutics include Bausch Health Companies (BHC), Perrigo (PRGO), Zai Lab (ZLAB), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Evotec (EVTCY), Schrödinger (SDGR) and PTC Therapeutics (PTCT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology Group (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.60%), NEA Management Company LLC (8.71%), Consonance Capital Management LP (5.06%), State Street Corp (4.31%), Sarissa Capital Management LP (4.14%) and Alkeon Capital Management LLC (2.26%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Enterprise Associates 14 New, Eva M Jack, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, NEA Management Company LLC, AXA S.A., Wells Fargo & Company MN, Connor Clark & Lunn Investment Management Ltd., JPMorgan Chase & Co., Cubist Systematic Strategies LLC, and Thrivent Financial for Lutherans. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, Eva M Jack, Scott D Sandell, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics.

MRSN stock was purchased by a variety of institutional investors in the last quarter, including Alkeon Capital Management LLC, State Street Corp, Point72 Asset Management L.P., Sarissa Capital Management LP, Charles Schwab Investment Management Inc., Federated Hermes Inc., Teacher Retirement System of Texas, and BlackRock Inc.. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, Enterprise Associates 14 New, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $24.89.

Mersana Therapeutics has a market capitalization of $1.70 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 83 workers across the globe.

The official website for Mersana Therapeutics is www.mersana.com.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]